Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. - Wikidata - wikimedia - TriplyDB

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

http://www.wikidata.org/entity/Q35620114

about

Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease Obesity: Current and potential pharmacotherapeutics and targets.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Continuous Glucose Monitoring Versus Capillary Point-of-Care Testing for Inpatient Glycemic Control in Type 2 Diabetes Patients Hospitalized in the General Ward and Treated With a Basal Bolus Insulin Regimen.Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.Obesity dilemma: are there enough bariatric surgeons?GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Obstacles to optimal management of inpatient hyperglycemia in noncritically ill patients.Controversies in prediabetes: do we have a diagnosis?The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.Peripheral targets in obesity treatment: a comprehensive update.GLP-1: benefits beyond pancreas.Novel effective drugs for diabetic kidney disease? or not?Pharmacotherapy in the Management of Pediatric Obesity.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.Exenatide: pharmacokinetics, clinical use, and future directions.Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.Insulin amyloid at injection sites of patients with diabetes.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.Association between accelerometer-assessed physical activity and objectively measured hearing sensitivity among U.S. adults with diabetes.Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.Health Care and Mortality among Persons with Severe Mental Illness.Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.Dietary total antioxidant capacity and incidence of chronic kidney disease in subjects with dysglycemia: Tehran Lipid and Glucose Study.Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.Bariatric surgery - time to replace with GLP-1?Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: A Randomized, Double-blind, Placebo-Controlled Trial.Interference of common haemoglobin variants with the Tosoh G7 standard mode HbA1c method.

P2860

Q26827183-2EB136E7-5DAD-4D34-8DDF-3FC7B0DA46E6 Q30243992-03655EE1-DE26-4370-91A5-5CEB69EC119A Q30377441-56913E8E-39F2-48FE-B6C2-B9854A84A05B Q33566838-872E9371-E0DD-4342-9220-AEF74DB3E861 Q33737073-8A692364-F4DF-4AC6-8E25-4FCDA1875A72 Q34405101-A98573BC-34D2-4658-96C1-F5C9AD8503B2 Q35209811-CFFD534C-416E-4BB6-ABB6-A4D1B48C1CA1 Q35668745-A5053C04-338A-4E2A-B171-D33F64AD5E1A Q36005314-0C1EA8D1-4A0F-43BF-AC2B-02BCD08B5088 Q36248001-42C1E6DB-5054-4B92-A896-EB5937746EC2 Q36406821-D9AE0823-30A7-44F8-A75B-2AC300B65836 Q36638877-43912053-5C7B-44A5-993A-370999646AA6 Q36942260-D2B7D400-9DBB-4A87-BC0F-5DB3AD897F71 Q36957423-15C1276F-59AF-47B5-806D-BE32704A2F91 Q37510130-94AF3D96-C453-4086-AFCA-1576B9B92746 Q37568754-E7E33E2D-1C29-4802-B7DB-74DFC79F4CC8 Q38012070-32F06F7C-7207-4AEC-9ABD-86D9E5D38FE7 Q38036774-B8B19FFB-121D-4D00-AC99-9AA1CE827791 Q38101677-503B57F7-7565-4753-8C16-976F363E6737 Q38194649-1C759DD0-3A73-465A-A7F8-FEF8B1E2ED90 Q38238288-C52A22AB-4D67-40CD-9266-FAD67673556B Q38265818-F28BA15F-5CFF-4C6A-A2CB-78B3062BD4C9 Q38667323-B1625E1B-F699-41C8-A70A-86297B6DFFD5 Q38708352-50590B8C-D682-4E3E-BE67-1BABF648826F Q38770746-AB46D7DC-5BDC-475C-AB6C-EF1F552710CD Q38794395-FB385813-48A7-4FD2-98F6-73DF375DB27E Q38820528-6ACC7CBA-3D52-48C5-961A-82708AD1F9A5 Q38829576-91AF89F0-37BF-4FE4-84B0-9569E340D6B4 Q38937735-A484F0DC-4BA8-40E3-9C51-44B33D2DBEC1 Q38982510-972E9F6D-7F68-40FC-AA8F-B0A68D107B3C Q39142473-B2F03D40-5717-491F-AE86-2C8DC58928DE Q39699152-F3ECA859-7C01-4820-8F8D-05FCF0D04068 Q41582462-EF4CBE35-6118-44D5-AAC8-DDB478FABA16 Q41635985-C839ED4E-746A-4FB7-BE1E-FB7E71FE46CC Q47652208-1C573685-8842-4501-9CF5-DE18D9D0F6A5 Q47753107-732A4F12-ADA4-4C89-A24F-DE5E1DCC82BB Q48129687-701ECCC5-3215-4B1C-968A-FEAD30F7B6FD Q50853618-5BC8DD7D-FCF3-4B5C-8D6F-4B1E530AD5A6 Q51732619-8F84E206-C6BE-4938-851B-48DC4EE322DF Q53170138-60FC7DD3-06DA-4C22-A27C-CE5498D926D6

P2860

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

http://www.wikidata.org/entity/Q35620114

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Short-term exenatide treatment ...... obese women without diabetes.

@ast

Short-term exenatide treatment ...... obese women without diabetes.

@en

type

label

Short-term exenatide treatment ...... obese women without diabetes.

@ast

Short-term exenatide treatment ...... obese women without diabetes.

@en

prefLabel

Short-term exenatide treatment ...... obese women without diabetes.

@ast

Short-term exenatide treatment ...... obese women without diabetes.

@en

P1433

Q35620114-0FCE949D-434E-44FE-99C1-F68628B13AF1

P1476

Q35620114-3E176E74-D779-4489-8F2D-74562F8F12D2

P2093

Q35620114-1D635751-431D-432D-846A-86D2C84A0F53

Q35620114-1FC31C2E-A275-4EB7-B8C7-9352C4342449

Q35620114-38DE6FFF-6F9F-4103-A94F-027904E8C6AE

Q35620114-8F197B6F-05AC-4A38-9A81-F301FBECE90D

Q35620114-94B18574-54F9-433C-A289-AD43017B6EF7

Q35620114-D439B683-90D1-472B-B0DE-CCBD51E8ABC1

Q35620114-F76E81E4-BA6E-40B0-A650-88A3C1347404

P2860

Q35620114-0B13F609-58E7-4F5F-8655-4E0859CDC6BE

Q35620114-11A200BF-DD6E-480C-9A6D-4D65311EF3C0

Q35620114-15500FD8-E984-44E0-9ED2-5785F94B321D

Q35620114-225A2F11-C973-4CF6-AA03-F93AAE9E416E

Q35620114-233141EF-CFE7-4AC9-B185-C6752075F644

Q35620114-2F945E31-B735-41B0-95D4-3E873055E752

Q35620114-3AA0ACAB-3DB8-45A4-8E40-DC02DCF5B514

Q35620114-6E20D666-BF22-4134-A82E-D65D0EC60C6D

Q35620114-6EE44188-BFA9-4B10-BCD3-948095A6AFD7

Q35620114-7A41BB88-9454-4A7F-9982-952ED6895CAF

P304

Q35620114-8FE56674-A246-42CC-9271-FDDF16CBEB94

P31

Q35620114-D6E3387B-ACB1-4EE7-B0CD-E00548C0B65C

P356

Q35620114-9599D9FC-DF16-4D63-BFAD-FD32B1B0139C

P407

Q35620114-9E2E2DD1-26DC-466C-83CB-3D24E39232A4

P433

Q35620114-58752E97-414F-43C3-9818-8D8550C7C42D

P478

Q35620114-E078F8D8-F873-4C11-AE24-A70CABE37203

P50

Q35620114-F6BEC897-7573-44CD-9E62-56D69D364069

P577

Q35620114-3CF6B496-664E-4D58-BAFC-FAE2D8181080

P5875

Q35620114-65E8D4F1-3091-4D94-8541-473E2CE95C72

P698

Q35620114-2072B125-5A26-4D5A-AAD1-B0F377F25D35

P921

Q35620114-A359C678-C3DA-435D-8BCF-057910808B06

P932

Q35620114-72B8690A-3910-4D64-A783-74B1757472DB

P356

P1433

P1476

Short-term exenatide treatment ...... obese women without diabetes.

@en

P2093

Chuanyun Gao

http://www.w3.org/2001/XMLSchema#string

Elissa Wilker

http://www.w3.org/2001/XMLSchema#string

Emilie K Mitten

http://www.w3.org/2001/XMLSchema#string

Gosala S Gopalakrishnan

http://www.w3.org/2001/XMLSchema#string

Janet Mullington

http://www.w3.org/2001/XMLSchema#string

Jody Dushay

http://www.w3.org/2001/XMLSchema#string

Meghan Crawley

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Long-term weight-loss maintenance: a meta-analysis of US studies.

Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial

Present and future: pharmacologic treatment of obesity

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

The cardiovascular effects of GLP-1 receptor agonists.

Adaptive thermogenesis in humans

P304

4-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-0931

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Eleftheria Maratos-Flier

P577

2011-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51758216

http://www.w3.org/2001/XMLSchema#string

P698

22040840

http://www.w3.org/2001/XMLSchema#string

P921

P932

3241299

http://www.w3.org/2001/XMLSchema#string